more_reports

Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial

Research Report
  ()
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton.
Tags: Biotechnology / Pharmaceuticals

New Jersey Biotech Reports Positive Survival Data

Research Report
  ()
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price.
Tags: Biotechnology / Pharmaceuticals

California Biotech's Target Price 200% Higher Than Current

Research Report
  ()
F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients.
Tags: Biotechnology / Pharmaceuticals

Target Price Raised on Biotech Co.

Research Report
  ()
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company.
Tags: Biotechnology / Pharmaceuticals

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment

Research Report
  ()
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note.
Tags: Biotechnology / Pharmaceuticals

AI Collaboration to Streamline Healthcare Administration and Improve Patient Outcomes

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers.
Tags: Healthcare Services

Revolutionizing Chronic Disease Treatment Through Regenerative Medicine

  ()
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential.
Tags: Medical DevicesBiotechnology / Pharmaceuticals

Implanted Cell Device Reaches 5 Year Milestone

Research Report
  ()
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report.
Tags: Medical DevicesRegenerative Medicine

Is It Now Time To Buy This Biotech Stock?

Contributed Opinion
  ()
Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Co's. Cell Pouch Performs Well in Study

Research Report
  ()
Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report.
Tags: Regenerative MedicineMedical Devices

Trial Data Help Position Cell Pouch for Commercial Success

Research Report
  ()
The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report.
Tags: Medical DevicesRegenerative Medicine

California Biotech Reports Positive QOL Improvements in Program

Research Report
  ()
With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months of data collected through its implementation of ReQoL, Roth MKM analyst Dr, Jonathan Schoff gave the company a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment

  ()
Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) has released new data that show success in using its Cell Pouch Transplant System to help Type 1 diabetes patients reach insulin independence. One author says the company is David taking on Goliath in the race for a cure.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Biotech Working on 'Functional Cure' for Type 1 Diabetes

  ()
Clinical-stage biotechnology company Sernova Corp.'s (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) Cell Pouch implantable technology can act as a "pseudo-organ," delivering therapeutic cells to the body. Find out why one newsletter author thinks the stock could deliver a big payoff for shareholders and for patients.
Tags: Biotechnology / Pharmaceuticals

MA Biotech Reports Positive Meeting with FDA

Research Report
  ()
Replimune Group Inc.'s (REPL:NASDAQ) announced a successful pre-Biologics License Application (BLA) meeting with the FDA, according to a Roth MKM research note.
Tags: Biotechnology / Pharmaceuticals

Healthcare Tech Firm and Leading University to Join Forces

  ()
The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform.
Tags: Life Sciences Tools & DiagnosticsTechnology

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Mass. Biopharma Reports Positive Data and Announces New Program

Research Report
  ()
Wedbush analysts noted that they would be buyers ahead of Vor Biopharma Inc.'s (VOR:NASDAQ) planned regulatory updates and likely further data readouts.
Tags: Biotechnology / Pharmaceuticals

Pharma Co. Enrolls First Patient in Trial

Research Report
  ()
Rigel Pharmaceuticals (RIGL:NASDAQ) recently announced the enrollment of the first patient in a Phase 1b/2 trial assessing decitabine and venetoclax in combination with Rezlidhia in mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), according to an H.C. Wainwright & Co. research note, which rated the stock a Buy.
Tags: Biotechnology / Pharmaceuticals

Florida Biotech Completes Enrollment in 'Pivotal' Drug Trial

  ()
Florida-based Cyclo Therapeutics Inc. (CYTH:NASDAQ) says it has completed enrollment in its "pivotal" TransportNPC trial of Niiemann-Pick Type C1, a rare progressive genetic disorder. Find out why analysts are recommending the stock.
Tags: Biotechnology / Pharmaceuticals

Long Term Care Co.'s Target Price Raised

Research Report
  ()
Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results.
Tags: Healthcare Services

AI Healthcare Co. Signs Partnership With Large Regional Health Plan

Research Report
  ()
Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note.
Tags: Life Sciences Tools & DiagnosticsHealthcare ServicesTechnology